TotalFinaElf sells 2.3% of Sanofi-Synthélabo

23-Apr-2001

TotalFinaElf announces the sale of 2.3% of the share capital of Sanofi-Synthélabo, or 16.7 million shares held by Elf Aquitaine, to be placed with institutional investors.

This sale is in line with the strategy announced by the Group.

Elf Aquitaine's 32.7% ownership of the share capital of Sanofi-Synthélabo before this transaction is reduced to 30.4% following the sale.

Other news from the department

Most read news

More news from our other portals

Discover the latest developments in battery technology!